Keflex (Cephalexin) for Non-Purulent Cellulitis Caused by MSSA
Cephalexin 500 mg orally four times daily for 5 days is the first-line treatment for non-purulent cellulitis caused by MSSA, with excellent efficacy (96% clinical success) and no need for routine MRSA coverage in typical cases. 1, 2, 3
Recommended Dosing
Adults
- Standard dose: 500 mg orally four times daily for skin and soft tissue infections 1, 2, 4
- The FDA-approved adult dosage range is 1–4 g daily in divided doses 4
- For more severe infections or less susceptible organisms, higher doses may be needed, but if >4 g daily is required, consider parenteral cephalosporins 4
Pediatric Patients
- 25–50 mg/kg/day divided into four doses (every 6 hours) 1, 2, 4
- For streptococcal pharyngitis and skin/soft tissue infections in children >1 year, the total daily dose may be divided every 12 hours 4
- For moderate cellulitis, high-dose cephalexin (75–100 mg/kg/day in 3–4 divided doses) showed 89.7% success rate in outpatient management 5
Duration of Therapy
A 5-day course is sufficient if clinical improvement is evident by day 5, with no additional benefit from extending therapy 6, 3. The 2014 IDSA guideline recommends considering extension only if the infection has not improved after 5 days 1. More recent 2019 NICE guidance supports 5–7 days total 6.
Why Cephalexin Works for MSSA Cellulitis
- Prospective data demonstrate 96% clinical success with β-lactam regimens (including cephalexin) in non-purulent cellulitis 3
- Cephalexin provides excellent coverage for β-hemolytic streptococci and methicillin-susceptible Staphylococcus aureus, the primary pathogens in typical non-purulent cellulitis 1, 2, 7
- It is rapidly absorbed after oral administration, achieving peak serum levels of approximately 18 mcg/mL at 1 hour after a 500 mg dose, with >90% excreted unchanged in urine within 8 hours 4
- Cephalexin remains cost-effective at current MRSA prevalence levels and is the most economical first-line choice for outpatient cellulitis management 8
When Cephalexin Is Appropriate
Routine MRSA coverage is NOT indicated for typical non-purulent cellulitis; cephalexin alone is sufficient unless high-risk features are present 1, 2, 3. Use cephalexin when:
- The cellulitis is non-purulent (no abscess or purulent drainage) 6, 3
- The patient has no systemic toxicity (no fever >38°C, tachycardia >90 bpm, tachypnea >24 breaths/min, or WBC >12,000 or <4,000 cells/μL) 1, 2
- There is no penetrating trauma (especially injection drug use) 6, 3
- The patient has no documented MRSA colonization elsewhere 6, 3
- There is no history of treatment failure with β-lactams in the prior 48–72 hours 3
When to Add or Switch to MRSA Coverage
Add MRSA-active therapy only when high-risk features are present 1, 2, 3:
- Lack of clinical response after 48–72 hours of cephalexin 3
- Purulent drainage or exudate (purulent phenotype) 6, 3
- Penetrating trauma (especially injection drug use) 6, 3
- Documented MRSA colonization elsewhere 6, 3
- Systemic inflammatory response syndrome (SIRS) or hypotension 1, 2
MRSA-Active Alternatives
If MRSA coverage is needed, switch to or add:
- Clindamycin 300–450 mg orally three times daily (provides dual streptococcal and MRSA coverage as monotherapy) 1, 2, 3
- Trimethoprim-sulfamethoxazole 1–2 double-strength tablets twice daily PLUS a β-lactam (TMP-SMX lacks reliable streptococcal activity) 1, 2, 3
- Doxycycline 100 mg twice daily PLUS a β-lactam (doxycycline also lacks reliable streptococcal activity) 1, 2, 3
Penicillin Allergy Considerations
Cephalexin remains appropriate for patients with non-immediate (non-IgE-mediated) penicillin allergy 1, 2, 3. For patients with immediate hypersensitivity reactions to penicillin, use clindamycin instead 1, 2.
Monitoring and Reassessment
- Reassess at 48–72 hours to confirm improvement in erythema, swelling, and tenderness 3
- If no improvement by day 5, switch to an MRSA-active regimen and consider imaging to exclude abscess or deeper infection 3
- Elevate the affected limb to facilitate edema drainage and accelerate clinical response 3
Common Pitfalls to Avoid
- Do not extend therapy beyond 5 days in patients who are clinically improving; this constitutes overtreatment 6, 3
- Do not use TMP-SMX or doxycycline as monotherapy for non-purulent cellulitis; they lack reliable streptococcal activity and must be combined with a β-lactam 3
- Avoid adjunctive rifampin; it provides no benefit and promotes resistance 9, 3
- Routine blood cultures or imaging are unnecessary for typical outpatient cellulitis; reserve them for severe systemic features, immunosuppression, or atypical exposures 3
- Do not routinely cover MRSA in typical non-purulent cellulitis; even with rising community-acquired MRSA rates, coverage is generally not recommended 7
Emerging Evidence on High-Dose Cephalexin
High-dose cephalexin (1000 mg four times daily in adults) showed fewer treatment failures (3.2% vs 12.9%) compared to standard dosing (500 mg four times daily), though with a higher proportion of minor adverse effects 10. In children with moderate cellulitis, high-dose cephalexin (75–100 mg/kg/day) achieved an 89.7% success rate and potentially reduces hospitalization rates 5. However, these remain investigational dosing strategies not yet incorporated into formal guidelines 10, 5.
Special Populations
- Pregnancy: Cephalexin is generally safe; avoid TMP-SMX in the third trimester and all tetracyclines throughout pregnancy 3
- Children <8 years: Avoid tetracyclines (including doxycycline and minocycline) 1, 2, 3
- Elderly patients on ACE inhibitors or with renal insufficiency: TMP-SMX increases the risk of hyperkalemia 3
- Infants 7–60 days old: Cephalexin 25 mg/kg/dose every 6 hours achieves necessary pharmacodynamic targets for Enterobacterales and MSSA 11
Storage and Administration
After mixing oral suspension, store in refrigerator and use within 14 days without significant loss of potency 4. Cephalexin is acid-stable and may be given without regard to meals 4.